|
F3680
|
|
10058-F4 ≥98% (HPLC), solid
|
10058-F4 is a c-Myc inhibitor that induces cell-cycle arrest and apoptosis. It is a cell-permeable thiazolidinone that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression. 10058-F4 inhibits tumor cell growth in a c-Myc-dependent manner both in vitro and in vivo (64 mM using c-Myc transfected Rat1a fibroblasts).
|
DMSO: >10 mg/mL H2O: <2 mg/mL
|
|
|
|
|
SRP5165
|
|
BAG1 (72-end), GST tagged human recombinant, expressed in E. coli, ≥70% (SDS-PAGE), buffered aqueous glycerol solution
|
|
|
|
|
|
|
B1436
|
|
BAX Inhibiting Peptide V5 ≥97% (HPLC), lyophilized powder
|
Bax-mediated apoptosis inhibitor; membrane permeable pentapeptide based on the Ku70-Bax inhibiting domain.
|
|
|
|
|
|
B2938
|
|
BEPP monohydrochloride ≥98% (HPLC)
|
BEPP is a double-strand RNA-dependent protein kinase (PKR) activator. The double-strand RNA (dsRNA)-dependent protein kinase is a ubiquitously expressed serine threonine kinase, inducible by interferon γ. PRK is involved in several curtail cellular regulations including phosphorylation of eIF2α (which leads to inhibition of protein synthesis and eliciting antivirus and antitumor activities), modulating activities of eIF2α, NF-κB, ATF-3, and p53. BEPP also inhibits the growth of a human lung cancer cell line overexpressing PKR.
|
DMSO: >10 mg/mL
|
|
|
|
|
B0186
|
|
BI-6C9 ≥97% (HPLC), solid
|
BI-6C9 is a tBid inhibitor and antiapoptotic.
|
DMSO: >20 mg/mL
|
|
|
|
|
SML0121
|
|
BTZO-1 ≥98% (HPLC)
|
BTZO-1 is a suppressor of cardiomyocyte apoptosis presumably by activation of antioxidant response element (ARE)-mediated gene expression. BTZO-1 binds to the macrophage migration inhibitory factor (MIF) that is required to activate the glutathione S-transferase Ya subunit (GST Ya) gene ARE.
|
DMSO: ≥7 mg/mL
|
|
|
|
|
B6179
|
|
Bongkrekic acid solution from Pseudomonas cocovenenans, ≥95% (HPLC), ~1 mg/mL
|
An antiapoptotic agent, it protects against NMDA receptor induced neuronal apoptosis, extends cell survival in cells undergoing apoptosis following infection with viral vectors and abrogates apoptosis induced by hydrogen peroxide in T-cells. It is an inhibitor of adenine nucleotide translocase, which is a component of the mitochondrial permeability transition (MPT) pore complex. Bongkrekic acid prevents mitochondrial depolarization, swelling, rupture of mitochondrial outer membrane, and release of apoptogenic proteins such as cytochrome c. This phenomenon was observed during staurosporine induced apoptosis in Jurkat cells, in HepG2 undergoing apoptosis following TNF-α and ethanol.
|
|
|
|
|
|
SML0068
|
|
CTP Inhibitor ≥98% (HPLC)
|
CTP Inhibitor is an inhibitor of mitochondrial citrate transport protein, was the first purely competitive inhibitor to be discovered and is more potent than BTC.
|
DMSO: ≥23 mg/mL
|
|
|
|
|
C8999
|
|
Calpeptin is a rho kinase activator and an inhibitor of calpains, a family of calcium-dependent cysteine proteases involved in apoptosis, long-term potentiation in neurons, and cell cycle progression.
|
DMSO: soluble15 mg/mL, clear
|
|
|
|
|
C7495
|
|
Clofarabine ≥98% (HPLC)
|
Clofarabine is a purine nucleoside antimetabolite. Clofarabine is toxic to nondividing lymphocytes and monocytes.
|
DMSO: >10 mg/mL
|
|
|
|
|
C7744
|
|
Combretastatin A4 ≥98% (HPLC), powder
|
Combretastatin A4 is a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest, and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A4 is a natural stilbenoid phenol.
|
DMSO: >10 mg/mL
|
|
|
|
|
P4236
|
|
Cyclic Pifithrin-α hydrobromide ≥98% (HPLC)
|
A stable analog of Pifithrin-α (Product Code P4359) with similar biological activities and lower cellular toxicity.
|
DMSO: soluble20 mg/mL
|
|
|
|
|
SML0183
|
|
EM20-25 ≥98% (HPLC)
|
EM20-25 is an analog of HA14-1 that antagonizes the effects of the anti-apoptotic protein BCL-2, and causes opening of the mitochondrial permeability transition pore. Unlike HA14-1, EM20-25 does not effect mitochondrial respiration.
|
DMSO: ≥5 mg/mL at ~60 °C
|
|
|
|
|
F5557
|
|
Fasentin ≥98% (HPLC)
|
Fasentin is a novel inhibitor of glucose uptake, GluT1 inhibitor. Fasentin is a novel inhibitor of glucose uptake that sensitizes cells to FAS-induced cell death. Fasentin selectively sensitized to death ligands, but did not decrease FLIP expression. It alters expression of genes associated with nutrient and glucose deprivation. Fasentin interacted with a unique site in the intracellular channel of the glucose transport protein GLUT1.
|
DMSO: >10 mg/mL
|
|
|
|
|
SML0583
|
|
Ferrostatin-1 is a potent inhibitor of non-apoptotic cell death induced by erastin call ferroptosis. Ferrostatin-1 prevents ferroptopic cell death in cancer cells and glutamate-induced toxicity in organotypic rat brain slices. It appears that Ferrostatin-1 controls lipid soluble ROS.
|
DMSO: soluble10 mg/mL, clear
|
|
|
|
|
G9420
|
|
GNF-2 ≥98% (HPLC), solid
|
GNF-2 belongs to a new class of Bcr-abl inhibitors. GNF-2 appears to bind to the myristoyl binding pocket, an allosteric site distant from the active site, stabilizing the inactive form of the kinase. It inhibits Bcr-abl phosphorylation with an IC50 of 267 nM, but does not inhibit a panel of 63 other kinases, including native c-Abl, and shows complete lack of toxicity towards cells not expressing Bcr-Abl. GNF-2 shows great potential for a new class of inhibitor to study Bcr-abl activity and to treat resistant Chronic myelogenous leukemia (CML), which is caused the Bcr-Abl oncoprotein.
|
DMSO: ≥5 mg/mL H2O: <2 mg/mL
|
|
|
|
|
SML0412
|
|
IM-54 ≥98% (HPLC)
|
IM-54 is a cell permeable, potent and selective inhibitor of necrosis. The compound inhibits necrosis induced by oxidative stress. IM-54 does not inhibit apoptosis induced by anticancer drugs.
|
DMSO: soluble5 mg/mL (clear solution)
|
|
|
|
|
M6690
|
|
MDL 28170 ≥95% (HPLC)
|
MDL 28170 is a potent cell permeable calpain I and II inhibitor; reduces capsaicin-mediated cell death in cultured dorsal root ganglion neurons. Reduced occurrence of apoptosis in H2O2 and A23187 treated PC12 cells. γ-secretase-inhibitor.
|
DMSO: soluble26 mg/mL H2O: insoluble methanol: soluble
|
|
|
|
|
M0199
|
|
Mdivi-1 ≥98% (HPLC), powder
|
Mdivi-1 is a cell-permeable selective inhibitor of mitochondrial division DRP (dynamin-related GTPase) and inhibitor of the mitochondrial division dynamin (Dnm1). Mitochondrial fusion and division play important roles in the regulation of apoptosis. Mdivi-1 is the first selective inhibitor of mitochondrial division dynamins. In principle, Mdivi-1 represents a class of therapeutics for stroke, myocardial infarction, and neurodegenerative diseases.
|
DMSO: >20 mg/mL
|
|
|
|
|
SML0629
|
|
Mitochondrial Fusion Promoter M1 is a cell permeable hydrazone that enhances mitochondrial fusion. M1 protects cells from mitochondrial fragmentation associated cell death. Mitochondrial Fusion Promoter M1 does not interfere with endoplasmic reticula (ER) and lysosomes morphology.
|
DMSO: soluble10 mg/mL, clear
|
|
|
|
|
E1271
|
|
N-Ethylmaleimide BioXtra, ≥98% (HPLC)
|
Augments currents from native M-channels in sympathetic neurons and acts as an opener for KCNQ2, KCNQ4 and KCNQ5 channels. Sulfhydryl alkylating agent that inactivates NADP-dependent isocitrate dehydrogenase and many endonucleases.
|
95% ethanol: soluble50 mg/mL, clear to slightly hazy (colorless to faint yellow)
|
|
|
|
|
E3876
|
|
N-Ethylmaleimide crystalline, ≥98% (HPLC)
|
Augments currents from native M-channels in sympathetic neurons and acts as an opener for KCNQ2, KCNQ4 and KCNQ5 channels. Sulfhydryl alkylating agent that inactivates NADP-dependent isocitrate dehydrogenase and many endonucleases.
|
|
|
|
|
|
N7787
|
|
NS3694 ≥98%, powder
|
NS3694 is an Inhibitor of apoptosome formation.
|
DMSO: soluble22 mg/mL H2O: insoluble <5 mg/mL
|
|
|
|
|
N1413
|
|
NSCI ≥97% (HPLC), solid
|
NSCI is a nonpeptide caspase 3 selective inhibitor.
|
DMSO: >10 mg/mL H2O: insoluble
|
|
|
|
|
N9037
|
|
Necrostatin-1 ≥98% (HPLC)
|
Necrostatin-1 is an inhibitor of necroptosis (non-apoptotic cell death pathway).
|
DMSO: >10 mg/mL
|
|
|
|
|
O9639
|
|
Oridonin ≥98% (HPLC), solid
|
Oridonin has potent anti-tumor activity. Oridonin targets AE (AML1-ETO) oncoprotein. Exposure to oridonin induces apoptosis in AE-bearing leukemic cells through the activation of intrinsic apoptotic pathway and triggering a caspase-3-mediated degradation of AE at D188. The compound also prolonged the lifespan of C57 mice bearing truncated AE-expressing leukemic cells without side effects like suppression of bone marrow or reduction of body weight of animals, and exerted synergic effects while combined with cytosine arabinoside. Additionally, oridonin inhibited tumor growth in nude mice inoculated with t(8;21)-harboring Kasumi-1 cells.
|
DMSO: >20 mg/mL H2O: insoluble
|
|
|
|
|
SML0402
|
|
PD 151746 ≥98% (HPLC)
|
PD 151746 is a potent inhibitor of calpains 1 and 2.
|
DMSO: soluble15 mg/mL (clear orange solution)
|
|
|
|
|
SML0021
|
|
PDI inhibitor 16F16 ≥98% (HPLC)
|
16F16 is a protein disulfide isomerase (PDI) inhibitor, first identified in a screen for compounds that prevent apoptosis induced by mutant huntingtin protein. 16F16 not only suppressed apoptosis induced by the misfolded protein mutant hungtingtin, it also protected rat neurons from cell death triggered by Aβ peptide. The actions of this inhibitor helped to identify a new mechanism in which a cell death pathway is regulated by protein misfolding via PDI upregulation.
|
DMSO: ≥12 mg/mL
|
|
|
|
|
SML0508
|
|
Pentostatin is a ring-expanded nucleoside (REN) that potently inhibits adenosine deaminase inhibitor, which leads to lymphocyte toxicity. Pentostatin is used as anticancer agent to treat leukemia (hairy cell leukemia and chronic lymphocytic leukemia) and is investigated as an agent to treat graft-versus-host disease (GVHD).
|
H2O: soluble10 mg/mL, clear
|
|
|
|
|
P4359
|
|
Pifithrin-α ≥95% (HPLC), powder
|
Pifithrin-α is a reversible inhibitor of p53-mediated apoptosis and p53-dependent gene transcription such as cyclin G, p21/waf1, and mdm2 expression. Pifithrin-α enhances cell survival after genotoxic stress such as UV irradiation and treatment with cytotoxic compounds including doxorubicin, etopoxide, paclitaxel, and cytosine-β-D-arabinofuranoside. Pifithrin-α protects mice from lethal whole body γ-irradiation without an increase in cancer incidence. The protective effect is not seen in p53-null mice or cells expressing a dominant negative mutant of the p53 gene. Protection is conferred by the transient expression of p53 in p53-deficient cell lines.
|
DMSO: soluble20 mg/mL
|
|
|
|
|
P0122
|
|
Pifithrin-μ ≥97% (HPLC), solid
|
Pifithrin-μ is an inhibitor of p53 binding and anti-apoptotic, which directly inhibits p53 binding to mitochondria as well as to Bcl-xL and Bcl-2 proteins. PFTμ rescues cells from lethal γ-irradiation-induced cell death. Because pifithrin-μ shuts down only the p53-mitochondrial pathway without affecting the transcriptional functions of p53, it is superior to pifithrin-α.
|
DMSO: >10 mg/mL H2O: <2 mg/mL
|
|
|
|
|
SML0221
|
|
Piperlongumine ≥97% (HPLC)
|
Piperlongumine selectively kills cancer cells regardless of p53 status without harming normal cells. It binds to and inihbits proteins known to regulate oxidative stress, in particular, Glutathione S-transferase pi 1 (GSTP1). It increases the level of reactive oxygen species (ROS) and apoptotic cell death in cancer cells with little effect on either rapidly or slowly dividing primary normal cells. Piperlongumine showed significant antitumour effects in a variety of mouse tumour models and inhibited growth of spontaneously formed malignant breast tumours and their associated metastases.
|
DMSO: ≥5 mg/mL at warmed to 60 °C
|
|
|
|
|
SML0108
|
|
R18 trifluoroacetate ≥98% (HPLC)
|
R18 is a competitive inhibitor of the 14-3-3 scaffolding proteins. It binds to the general binding groove of 14-3-3. R18 blocks 14-3-3 interaction with most or all of its client proteins.
|
|
|
|
|
|
S5944
|
|
S-15176 difumarate salt ≥98% (HPLC), solid
|
Antioxidant and anti-ischemic agent. Also inhibits mitochondrial permeability transition, prevents the early step in apoptosis by preventing collapse of the electrochemical gradient across the mitochondrial membrane. IC50 for in vitro lipid peroxidation is 0.3 μM. IC50 for carnitine palmitoyltransferase (CPT-1) in heart homogenate is 16.8 μM. The shift from fatty acid to glucose oxidation may contribute to anti-ischemic effect.
|
DMSO: soluble16 mg/mL H2O: insoluble
|
|
|
|